Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10072140 | American Journal of Ophthalmology | 2005 | 8 Pages |
Abstract
Over the 3 months of treatment, Trav/Tim produced clinically relevant IOP reductions in patients with open-angle glaucoma or ocular hypertension that were greater than those produced by either Trav or Tim alone. The clinical results that Trav/Tim was safe and well tolerated with an incidence of adverse events was comparable to the results of Trav or Tim alone. Trav/Tim provides both more effective IOP reduction than its components and the benefits of once-daily dosing.
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Howard S. MD, Silvia MD, Brian E. MD, John MD, Sushanta PhD, Theresa A. PhD, Michael V.W. PhD,